{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-004943","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.635519+00:00","generated_at":"2026-05-28T03:05:27.853209+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agios announces 2025 milestones: PYRUKYND PDUFA Sept 7; RISE UP topline in late 2025","bullets":["FDA accepted sNDA for PYRUKYND in thalassemia; PDUFA goal date September 7, 2025.","Phase 3 RISE UP topline results expected late 2025; potential U.S. commercial launch in 2026.","Received $1.1B in milestone payments: $905M from Royalty Pharma, $200M from Servier post vorasidenib approval.","Phase 3 ACTIVATE-Kids topline in early 2025; Phase 2b tebapivat enrollment completion late 2025.","IND filing planned for AG-236 siRNA in polycythemia vera mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-004943","json":"https://secwatch.observer/filing/0001193125-25-004943.json","markdown":"https://secwatch.observer/filing/0001193125-25-004943.md","text":"https://secwatch.observer/filing/0001193125-25-004943.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312525004943/0001193125-25-004943-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312525004943/d131665d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:05:27.853209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}